Total Payments
$10,346
2024 Payments
$8,869
Companies
15
Transactions
89
Medicare Patients
10,345
Medicare Billing
$9.3M
Payment Breakdown by Category
Consulting$4,940 (47.7%)
Food & Beverage$3,364 (32.5%)
Travel$2,042 (19.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,940 | 1 | 47.7% |
| Food and Beverage | $3,364 | 82 | 32.5% |
| Travel and Lodging | $2,042 | 6 | 19.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| OnMark, Inc. | $5,125 | 3 | $0 (2024) |
| US Oncology Corporate, Inc. | $1,739 | 3 | $0 (2024) |
| Kyowa Kirin, Inc. | $1,420 | 7 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $672.12 | 29 | $0 (2024) |
| Genentech USA, Inc. | $379.50 | 15 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $199.09 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $185.63 | 4 | $0 (2021) |
| Astellas Pharma US Inc | $151.45 | 5 | $0 (2024) |
| Allergan, Inc. | $147.83 | 9 | $0 (2020) |
| AbbVie Inc. | $111.73 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,869 | 34 | OnMark, Inc. ($5,125) |
| 2023 | $615.33 | 23 | Regeneron Healthcare Solutions, Inc. ($205.50) |
| 2022 | $373.04 | 12 | Bausch & Lomb Americas Inc. ($175.78) |
| 2021 | $76.10 | 4 | Regeneron Healthcare Solutions, Inc. ($53.56) |
| 2020 | $56.64 | 3 | Allergan, Inc. ($34.74) |
| 2019 | $293.42 | 9 | Novartis Pharmaceuticals Corporation ($141.19) |
| 2018 | $62.86 | 4 | Allergan Inc. ($44.52) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/08/2024 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $1,081.81 | General |
| 11/08/2024 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $601.04 | General |
| 11/07/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/21/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Ophthalmology | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/11/2024 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Food and Beverage | In-kind items and services | $37.68 | General |
| Category: Ophthalmology | ||||||
| 09/09/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $33.21 | General |
| Category: Ophthalmology | ||||||
| 09/03/2024 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $55.72 | General |
| 08/02/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $31.10 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: Ophthalmology | ||||||
| 07/12/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,940.00 | General |
| 07/12/2024 | OnMark, Inc. | — | Travel and Lodging | Cash or cash equivalent | $126.00 | General |
| 07/12/2024 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $59.01 | General |
| 07/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $31.89 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.59 | General |
| Category: Ophthalmology | ||||||
| 06/03/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $33.08 | General |
| Category: Ophthalmology | ||||||
| 04/30/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $30.16 | General |
| Category: Ophthalmology | ||||||
| 04/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/27/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | In-kind items and services | $266.09 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $104.70 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $73.91 | General |
| 04/27/2024 | Kyowa Kirin, Inc. | — | Food and Beverage | In-kind items and services | $46.29 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,831 | 18,697 | $3.7M | $2.7M |
| 2022 | 14 | 2,479 | 8,538 | $2.7M | $2.0M |
| 2021 | 14 | 2,358 | 8,241 | $2.8M | $2.2M |
| 2020 | 14 | 2,677 | 9,253 | $3.1M | $2.4M |
Total Patients
10,345
Total Services
44,729
Medicare Billing
$9.3M
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 222 | 2,146 | $2.1M | $1.5M | 71.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 35 | 7,140 | $264,518 | $207,381 | 78.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 51 | 1,680 | $257,914 | $202,205 | 78.4% |
| J3490 | Unclassified drugs | Office | 2023 | 50 | 115 | $230,613 | $168,627 | 73.1% |
| J0179 | Injection, brolucizumab-dbll, 1 mg | Office | 2023 | 19 | 642 | $203,107 | $159,234 | 78.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 386 | 1,613 | $205,722 | $156,036 | 75.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 379 | 1,078 | $137,009 | $92,943 | 67.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 441 | 946 | $84,798 | $60,691 | 71.6% |
| 92134 | Imaging of retina | Office | 2023 | 681 | 2,059 | $81,235 | $57,898 | 71.3% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 16 | 245 | $51,108 | $37,325 | 73.0% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 149 | 502 | $40,481 | $31,736 | 78.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $14,139 | $9,811 | 69.4% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 11 | 11 | $12,326 | $9,664 | 78.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 72 | 79 | $10,424 | $7,898 | 75.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 76 | 76 | $8,572 | $5,525 | 64.4% |
| 92250 | Photography of the retina | Office | 2023 | 100 | 160 | $5,849 | $4,193 | 71.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 46 | 48 | $2,683 | $1,754 | 65.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 72 | $79.12 | $61.92 | 78.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 218 | 2,054 | $2.0M | $1.5M | 75.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 357 | 1,386 | $177,353 | $134,234 | 75.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 353 | 1,146 | $146,974 | $105,888 | 72.0% |
| J0179 | Injection, brolucizumab-dbll, 1 mg | Office | 2022 | 17 | 390 | $122,003 | $96,024 | 78.7% |
| 92134 | Imaging of retina | Office | 2022 | 664 | 1,771 | $70,949 | $51,210 | 72.2% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 166 | 609 | $49,387 | $38,558 | 78.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 327 | 574 | $52,358 | $36,252 | 69.2% |
About Dr. Adam Berger, MD
Dr. Adam Berger, MD is a Retina Specialist healthcare provider based in Winter Haven, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972574408.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Berger, MD has received a total of $10,346 in payments from pharmaceutical and medical device companies, with $8,869 received in 2024. These payments were reported across 89 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($4,940).
As a Medicare-enrolled provider, Berger has provided services to 10,345 Medicare beneficiaries, totaling 44,729 services with total Medicare billing of $9.3M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Winter Haven, FL
- Active Since 02/01/2006
- Last Updated 06/04/2025
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1972574408
Products in Payments
- EYLEA (Biological) $400.51
- EYLEA HD (Biological) $305.97
- Vabysmo (Drug) $297.27
- OZURDEX (Drug) $259.56
- XIPERE (Drug) $199.09
- Izervay (Drug) $127.81
- BUPARLISIB (Drug) $121.75
- Cimerli (Biological) $100.43
- BEOVU (Drug) $63.88
- Lucentis (Biological) $58.93
- EVA, combined machine (Device) $37.68
- VABYSMO (Drug) $23.30
- EYLEA AFLIBERCEPT INJECTION (Biological) $18.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.